RML Hospital Demand Covishield, Not Covaxin Shots Citing ‘Lack of Complete Trial’
Raising concerns over the government’s vaccination drive against COVID-19, resident doctors at Delhi’s Ram Manohar Lohia Hospital on Saturday said they wanted to be administered the Serum Institute’s Covishield instead of Bharat Biotech’s Covaxin due to “apprehensions over lack of complete trial, ”The central government has, however, sought to underplay such apprehensions saying “a lot of work” had gone into the development of both vaccines.
“Covaxin manufactured by Bharat Biotech is being preferred over Covishield manufactured by Serum Institute in our hospital…We would like to bring to your notice that the residents are a bit apprehensive about the lack of complete trial in the case of Covaxin and might not participate in huge numbers thus defeating the purpose of the vaccination,” the Resident Doctors Association of the hospital said today in a letter to the medical superintendent of the facility.